# Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer

> **NCT00016341** · PHASE3 · TERMINATED · sponsor: **Gynecologic Oncology Group**

## Conditions studied

- Endometrial Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** cisplatin
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** megestrol acetate
- **DRUG:** paclitaxel
- **DRUG:** tamoxifen citrate

## Key facts

- **NCT ID:** NCT00016341
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-05
- **Primary completion:** 2003-10
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00016341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00016341, "Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00016341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*